Capstone Therapeutics, Inc. – "AEM-28 Drug Class May Serve Larger Cardiovascular Markets"

New York, NY / October 7, 2014 / Capstone Therapeutics CAPS today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his second blog post, Mr. Holliman outlines Capstone's work with Lipimetix and UAB in researching the full potential of the Company's lead peptide, AEM-28. With the development of the new AEM-28 analog, AEM-28-02, Mr. Holliman describes it as a "game changer" due to the longevity of its potential patent life and the larger cardiovascular markets which could be served. Read the full blog post from Mr. Jock Holliman on TheChairmansBlog.com (http://www.thechairmansblog.com/capstone-therapeutics/john-holliman/aem-28-drug-class-may-serve-larger-cardiovascular-markets/).

About Capstone Therapeutics

Capstone Therapeutics is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with cardiovascular disease. The Company is primarily focused on development and commercialization of Apo E Mimetic Peptide Molecule AEM-28 and its analogs (through the LipimetiX Development, LLC, joint venture). For more information, please visit the Company's website: http://www.capstonethx.com/

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com 

SOURCE: The Chairmans Blog